<DOC>
	<DOC>NCT00496730</DOC>
	<brief_summary>Prevalence of metabolic syndrome in korea is increasing. There is no clinical trial targeting on such increasing populations like metabolic syndrome patients with Vytorin® in korea. Therefore this trial will help evaluate the lipid lowering effect of Vytorin® in asian population with metabolic syndrome.</brief_summary>
	<brief_title>A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
	<criteria>Diagnosis of the metabolic syndrome according to 2005 American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI) scientific statement No history of diabetes and 100 &lt;=LDLC &lt;=250 mg/dl Myocardial Infarction, coronary artery bypass surgery, or angioplasty within 3 months Congestive heart failure defined by New York Heart Association (NYHA) class III or IV Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins Uncontrolled hypertension Unstable angina</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Metabolic Disorder</keyword>
</DOC>